Baillie Gifford's position in Vertex Pharmaceuticals is currently worth $57.1 Million. That's 0.05% of their equity portfolio (136th largest holding). The first Vertex Pharmaceuticals trade was made in Q4 2016. Since then Baillie Gifford bought shares nine more times and sold shares on five occasions. The investor's estimated purchase price is $58.6 Million, resulting in a loss of 2.4%.